Drug
Foretinib
Foretinib is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
withdrawn125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
NCT01147484
completedphase_1
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
NCT01138384
completedphase_1
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
NCT00920192
withdrawnphase_2
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
NCT02034097
Clinical Trials (4)
Showing 4 of 4 trials
NCT01147484Phase 2
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
NCT01138384Phase 1
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
NCT00920192Phase 1
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
NCT02034097Phase 2
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4